Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial
Gordon Sussman, Jacques Hébert, Wayne Gulliver, Charles Lynde, William H. Yang, Kim Papp, Melinda Gooderham, Olivier Chambenoit, Sam Khalil, Frederica DeTakacsy, António Vieira, Lenka Řihakova
Topics & Concepts
MedicineOmalizumabDosingClinical endpointRandomized controlled trialInternal medicineClinical trialSurgeryImmunoglobulin EAntibodyImmunologyUrticaria and Related ConditionsCoagulation, Bradykinin, Polyphosphates, and AngioedemaDrug-Induced Adverse Reactions